Spark Therapeutics Inc. (NASDAQ:ONCE) shares were up 4.6% on Friday . The stock traded as high as $58.19 and last traded at $57.94, with a volume of 844,432 shares. The stock had previously closed at $55.39.

Several research analysts have weighed in on ONCE shares. Evercore ISI started coverage on shares of Spark Therapeutics in a research report on Tuesday, April 12th. They set a “buy” rating and a $37.00 target price on the stock. Zacks Investment Research upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Thursday, April 14th. Chardan Capital restated a “neutral” rating on shares of Spark Therapeutics in a research report on Thursday, April 14th. Cowen and Company restated a “buy” rating and set a $75.00 target price on shares of Spark Therapeutics in a research report on Wednesday, May 4th. Finally, Wedbush restated an “underperform” rating and set a $21.00 target price on shares of Spark Therapeutics in a research report on Thursday, May 19th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Hold” and a consensus target price of $58.70.

The stock’s market cap is $1.59 billion. The stock’s 50-day moving average is $51.46 and its 200 day moving average is $39.72.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, May 4th. The company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.11. The company had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $1.48 million. The business’s quarterly revenue was down 43.2% compared to the same quarter last year. On average, analysts forecast that Spark Therapeutics Inc. will post ($3.81) EPS for the current fiscal year.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 25,000 shares of the firm’s stock in a transaction dated Thursday, May 19th. The shares were sold at an average price of $46.01, for a total transaction of $1,150,250.00. Following the transaction, the chief executive officer now owns 255,000 shares of the company’s stock, valued at approximately $11,732,550. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Anand Mehra sold 500 shares of the firm’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $60.00, for a total transaction of $30,000.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Spark Therapeutics stock. TD Asset Management Inc. increased its stake in shares of Spark Therapeutics Inc. (NASDAQ:ONCE) by 72.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 58,187 shares of the company’s stock after buying an additional 24,400 shares during the period. TD Asset Management Inc. owned 0.24% of Spark Therapeutics worth $2,636,000 as of its most recent filing with the SEC.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.